Constellations of Pathology in the Placenta and How They Relate to Clinical Conditions

  • Sanne J. GordijnEmail author
  • Alexander E. P. Heazell
  • Eoghan E. Mooney
  • Theonia K. Boyd


Interpretation and presentation of placental findings in a clinically accessible manner are important aspects of placental pathology. While symptoms and signs of placental disease may differ, certain clinical presentations are associated with characteristic placental pathology. This chapter expands on the clinical diagnosis of two important conditions, namely, hypertensive disorders of pregnancy and preterm rupture of membranes, and discusses the placental pathology typically seen with them.


Constellations Disease patterns Hypertension Preeclampsia Membrane rupture Inflammation 


  1. 1.
    Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4:97–104.CrossRefGoogle Scholar
  2. 2.
    Saudan P, Brown MA, Buddle ML, Jones M. Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol. 1998;105:1177–84.CrossRefGoogle Scholar
  3. 3.
    Panaitescu AM, Syngelaki A, Prodan N, Akolekar R, Nicolaides KH. Chronic hypertension and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol. 2017;50:228–35.CrossRefGoogle Scholar
  4. 4.
    Sarno L, Maruotti GM, Saccone G, Sirico A, Mazzarelli LL, Martinelli P. Pregnancy outcome in proteinuria-onset and hypertension-onset preeclampsia. Hypertens Pregnancy. 2015;34:284–90.CrossRefGoogle Scholar
  5. 5.
    Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.CrossRefGoogle Scholar
  6. 6.
    Broekhuijsen K, van Baaren GJ, van Pampus MG, et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. Lancet. 2015;385:2492–501.CrossRefGoogle Scholar
  7. 7.
    Lees C, Marlow N, Arabin B, Bilardo CM, et al. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol. 2013;42:400–8.CrossRefGoogle Scholar
  8. 8.
    Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374:979–88.CrossRefGoogle Scholar
  9. 9.
    Williams D. Pre-eclampsia and long-term maternal health. Obstet Med. 2012;5:98–104.CrossRefGoogle Scholar
  10. 10.
    Rasmussen S, Ebbing C, Linde LE, Baghestan E. Placental abruption in parents who were born small: registry-based cohort study. BJOG. 2018;125:667–74.CrossRefGoogle Scholar
  11. 11.
    Umbers AJ, Stanisic DI, Ome M, et al. Does malaria affect placental development? Evidence from in vitro models. PLoS One. 2013;8:e55269.CrossRefGoogle Scholar
  12. 12.
    Goodfellow LR, Batra G, Hall V, McHale E, Heazell AEP. A case of confined placental mosaicism with double trisomy associated with stillbirth. Placenta. 2011;32:699–703.CrossRefGoogle Scholar
  13. 13.
    Gordijn SJ, Beune IM, Thilaganathan B, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016;48:333–9.CrossRefGoogle Scholar
  14. 14.
    Papageorghiou AT, Ohuma EO, Altman DG, et al. International standards for fetal growth based on serial ultrasound measurements: the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project. Lancet. 2014;384:869–79.CrossRefGoogle Scholar
  15. 15.
    Gardosi J, Chang A, Kalyan B, Sahota D, Symonds EM. Customised antenatal growth charts. Lancet. 1992;339:283–7.CrossRefGoogle Scholar
  16. 16.
    Vollgraff Heidweiller-Schreurs CA, De Boer MA, Heymans MW, et al. Prognostic accuracy of cerebroplacental ratio and middle cerebral artery Doppler for adverse perinatal outcomes: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018;51:313–22.CrossRefGoogle Scholar
  17. 17.
    Conde-Agudelo A, Papageorghiou AT, Kennedy SH, Villar J. Novel biomarkers for predicting intrauterine growth restriction: a systematic review and meta-analysis. BJOG. 2013;120:681–94.CrossRefGoogle Scholar
  18. 18.
    Ganzevoort W, Alfirevic Z, von Dadelszen P, et al. STRIDER: Sildenafil Therapy In Dismal prognosis Early-onset intrauterine growth Restriction—a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev. 2014;3:23.CrossRefGoogle Scholar
  19. 19.
    Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2018;218:S829–40.CrossRefGoogle Scholar
  20. 20.
    Brosens I, Pijnenborg R, Vercruysse L, Romero R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204:193–201.CrossRefGoogle Scholar
  21. 21.
    Cooley SM, Reidy FR, Mooney EE, McAuliffe FM. Antenatal suspicion of ischemic placental disease and coexistence of maternal and fetal placental disease: analysis of over 500 cases. Am J Obstet Gynecol. 2011;205:576.e1–6.CrossRefGoogle Scholar
  22. 22.
    Schaaf JM, Ravelli AC, Mol BW, Abu-Hanna A. Reproductive outcome after early-onset pre-eclampsia. Hum Reprod. 2011;26:391–7.CrossRefGoogle Scholar
  23. 23.
    Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev. 2013;12:CD001058.Google Scholar
  24. 24.
    Roberts DJ, Celi AC, Riley LE, et al. Acute histologic chorioamnionitis at term: nearly always noninfectious. PLoS One. 2012;7:e31819.CrossRefGoogle Scholar
  25. 25.
    Johnson CT, Farzin A, Burd I. Current management and long-term outcomes following chorioamnionitis. Obstet Gynecol Clin N Am. 2014;41:649–69.CrossRefGoogle Scholar
  26. 26.
    Soper DE, Mayhall CG, Dalton HP. Risk factors for intraamniotic infection: a prospective epidemiologic study. Am J Obstet Gynecol. 1989;161:562–6. discussion 566–8.CrossRefGoogle Scholar
  27. 27.
    Salas AA, Faye-Petersen OM, Perelta-Carcelen M, et al. Histological characteristics of the fetal inflammatory response associated with neurodevelopmental impairment and death in extremely preterm infants. J Pediatr. 2013;163:652–7.e1–2.CrossRefGoogle Scholar
  28. 28.
    Ptacek I, Sebire NJ, Man JA, Brownbill P, Heazell AEP. Systematic review of placental pathology reported in association with stillbirth. Placenta. 2014;35:552–62.CrossRefGoogle Scholar
  29. 29.
    Kingdom JC, Audette MC, Hobson SR, Windrim RC, Morgen E. A placenta clinic approach to the diagnosis and management of fetal growth restriction. Am J Obstet Gynecol. 2018;218:S803–17.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Sanne J. Gordijn
    • 1
    Email author
  • Alexander E. P. Heazell
    • 2
  • Eoghan E. Mooney
    • 3
  • Theonia K. Boyd
    • 4
    • 5
    • 6
  1. 1.Department of Obstetrics and GynaecologyUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
  2. 2.Tommy’s Maternal and Fetal Health Research Centre, Faculty of Biology, Medicine and HealthUniversity of ManchesterManchesterUK
  3. 3.Department of Pathology and Laboratory MedicineNational Maternity HospitalDublinIreland
  4. 4.Division of Anatomic Pathology, Department of PathologyBoston Children’s HospitalBostonUSA
  5. 5.Division of Women’s and Perinatal PathologyBrigham and Women’s HospitalBostonUSA
  6. 6.Department of PathologyHarvard Medical SchoolBostonUSA

Personalised recommendations